Today: 19 July 2026
P&G Gives Up Weekly Gain With Next Test on Wednesday
30 May 2026
2 mins read

P&G Gives Up Weekly Gain With Next Test on Wednesday

NEW YORK, May 30, 2026, 10:01 EDT

Procter & Gamble shares slipped for the week, falling back on Friday and giving up most of their gains from Wednesday’s move. Now attention turns to finance chief Andre Schulten, who is set to appear on June 3.

U.S. markets stayed closed over the weekend, with the NYSE shut Monday for Memorial Day. The NYSE’s regular hours are 9:30 a.m. to 4:00 p.m. ET. Friday’s closing numbers are the most recent regular-session data for the Dow.

P&G dropped 1.61% to $143.56 on Friday, its second day lower. The S&P 500 picked up 0.22%, and the Dow Jones rose 0.72%. Colgate-Palmolive and Estee Lauder also slipped, so losses hit several consumer and personal-care shares, not just P&G.

P&G had been a support for the Dow earlier this week. Reuters said P&G jumped 3.2% on Wednesday, with healthcare and consumer stocks sending the Dow to a record close. That move briefly brought defensive, cash-generating stocks back into focus after a stretch of AI-driven gains.

P&G didn’t get much lift this week. Shares closed at $144.44 on May 22, slid Tuesday, popped 3.17% Wednesday, then dropped Thursday and Friday to finish at $143.56, a 0.6% loss for the shortened week.

Schulten is set to speak at the Deutsche Bank dbAccess Global Consumer Conference before the regular U.S. open on Wednesday. The presentation kicks off at 8:30 a.m. CEST, or 2:30 a.m. ET. P&G said the event will be webcast and a replay will be available.

Investors want to know if margin pressure at P&G is just a short-term problem. Last month, P&G reported fiscal third-quarter net sales up 7% to $21.2 billion. Organic sales, which cut out currency swings and deals, climbed 3%. Chief Executive Shailesh Jejurikar said the company saw “a solid acceleration in top-line results” and is pushing up investment even as the geopolitical and economic backdrop stays tough. P&G Investor

P&G stuck with its fiscal 2026 sales and earnings outlook, but said tariffs would eat about $400 million after tax. Commodity costs are another $150 million drag. With those, plus tax and interest partly offset by forex, the company said the headwind adds up to 25 cents per share and takes expected EPS to the low end of its range.

Schulten was blunt on the April earnings call. “The noise, I would call it, from the commodity exposure is significant,” he told Reuters. He also said the company had “a lot of work to do” on supply-chain and cost problems. Brian Jacobsen, chief economist at Annex Wealth Management, told Reuters oil is “ubiquitous” and that higher prices “seep into everything.” Reuters

P&G still gets some support from Wall Street, but expectations aren’t loose. MarketBeat’s analyst tracker lists a “Moderate Buy” from 20 analysts—11 buys, nine holds, and a $161.06 average target for the next 12 months. UBS raised its target to $172, but JPMorgan trimmed its number to $162, holding on to its overweight stance. MarketBeat

P&G is facing questions about whether its pricing power will hold up. If consumers start to resist price hikes, or tariffs and input costs stay high through the June quarter, the company may need to boost spending on promos and new products. Investors are watching for margin improvement. That sets up Wednesday’s remarks as a test for the stock’s defensive premium, not just another conference spot.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Molina Healthcare: Market Sentiment Misses the Mark
    July 19, 2026, 6:19 AM EDT. The market's reading of Molina Healthcare's valuation appears mistaken, opening a window for investors. An independent finance expert, experienced in macroeconomic analysis, technical patterns, and momentum-driven trading, makes the case that shares are currently undervalued. The analyst's method prioritises capital protection and a favourable risk-reward profile, blending Growth At A Reasonable Price (GARP) with momentum strategies for a balanced investment framework. The article highlights Molina Healthcare's prospects with actionable, data-backed observations in a turbulent market, encouraging investors to reassess the cautious outlook now prevailing.
Wolfspeed Stock Just Hit a Wall After Its AI Surge. The Risk Traders Can’t Ignore
Previous Story

Wolfspeed Stock Just Hit a Wall After Its AI Surge. The Risk Traders Can’t Ignore

Redwire Shares Jump 40% in Four Days — Eyes on Monday
Next Story

Redwire Shares Jump 40% in Four Days — Eyes on Monday

Go toTop